Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis

被引:75
作者
Aithal, GP
Day, CP
Leathart, JBS
Daly, AK
机构
[1] Newcastle Univ, Sch Med, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源
PHARMACOGENETICS | 2000年 / 10卷 / 06期
关键词
diclofenac; CYP2C9; polymorphism; hepatitis;
D O I
10.1097/00008571-200008000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The mechanism by which diclofenac-induced hepatotoxicity occurs is unclear, even though covalent modification of proteins by diclofenac metabolites appears to be important in pathogenesis, either by altering protein function or by eliciting an immune response. Adduct formation may be due to metabolism of diclofenac via an alternative pathway rather than via its major 4'-hydroxylation pathway mediated by the cytochrome P450 CYP2C9. We hypothesized that possession of variant CYP2C9 alleles might be a risk factor for diclofenac-induced hepatotoxicity, since the allelic variants CYP2C9*2 and CYP2C9*3 may be associated with impaired metabolism compared to the wild-type (CYP2C9*1). To investigate in more detail the effects of the polymorphisms on diclofenac metabolism in human liver, the kinetics of diclofenac cl-hydroxylation by human liver microsomes of known CYP2C9 >genotype were examined, An overall difference in V-max and Vmax/Km between samples homozygous for CYP2C9*1 and heterozygous for CYP2C9*2 or CYP2C9*3 was detected (P = 0.044). However, on subgroup analysis, there was no significant difference between samples homozygous for CYP2C9*1 and heterozygous for CYP2C9*2, although there was a borderline difference between the samples homozygous for CYP2C9*1 and those heterozygous for CYP2C9*3 (P = 0.057). The relationship between CYP2C9 genotype and susceptibility to diclofenac-induced hepatotoxicity was further examined by genotyping 24 patients with diclofenac-induced hepatotoxicity together with 100 healthy controls for the CYP2C9*2 and CYP2C9*3 alleles, CYP2C9 genotype frequencies for CYP2C9*2 and CYP2C9*3 were similar in patients and controls. To assess whether diclofenac-induced hepatotoxicity was due to rare CYP2C9 mutations, the upstream sequence (-1 to -1000) and all exons and exon-intron boundaries of CYP2C9 from four subjects who had suffered severe hepatotoxicity was determined. However, no ne rv polymorphisms were detected. We therefore found no evidence that polymorphism in CYP2C9 is a determinant of diclofenac-induced hepatotoxicity, Pharmacogenetics 10:511-518 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:511 / 518
页数:8
相关论文
共 29 条
  • [1] Aithal PG, 1998, HEPATOLOGY, V28, p256A
  • [2] BANKS AT, 1995, HEPATOLOGY, V22, P820, DOI 10.1002/hep.1840220320
  • [3] BENICHOU C, 1990, J HEPATOL, V11, P272
  • [4] Bort R, 1999, J PHARMACOL EXP THER, V288, P65
  • [5] Bougie D, 1997, BLOOD, V90, P407
  • [6] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [7] The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
    Crespi, CL
    Miller, VP
    [J]. PHARMACOGENETICS, 1997, 7 (03): : 203 - 210
  • [8] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [9] Clinical pharmacokinetics of diclofenac - Therapeutic insights and pitfalls
    Davies, NM
    Anderson, KE
    [J]. CLINICAL PHARMACOKINETICS, 1997, 33 (03) : 184 - 213
  • [10] DICLOFENAC COVALENT PROTEIN-BINDING IS DEPENDENT ON ACYL GLUCURONIDE FORMATION AND IS INVERSELY RELATED TO P450-MEDIATED ACUTE CELL INJURY IN CULTURED RAT HEPATOCYTES
    KRETZROMMEL, A
    BOELSTERLI, UA
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1993, 120 (01) : 155 - 161